1-13 December 2018 | Geneva, Switzerland UNAIDS Programme Coordinating Board Issue date: 23 November 2018
UNAIDS/PCB (43)/18.32
В данной главе мы рассмотрим изменения, реализованные в DSM5, касающиеся не всех психических расстройств. Ниже мы остановимся на модификациях, представляющих инт...ерес для детских и подростковых психиатров, и на тех, которые вызывают полемику
more
Dans la présente étude, le Haut-Commissariat des Nations Unies aux droits de l’homme expose les normes relatives à l’égalité et à la non discrimination à l’égard des personnes handicapées à la lumière de l’article 5 de la Convention relative aux droits des personnes handicapées. ...Il formule des orientations pour l’application de l’article 5 de la Convention, présente les bonnes pratiques recensées et émet des recommandations.
more
Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infe...ction
WHO/CDS/HIV/18.28
more
Aлгоритм лабораторной диагностики и мониторинга лечения туберкулеза легких и туберкулеза с лекарственной устойчивостью на основе применения современных быстрых... молекулярных методов.
Экспертное заключение членов основной группы Европейской лабораторной инициативы, подготовленное для Европейского региона ВОЗ.
more
Expert opinion of the European Tuberculosis Laboratory Initiative core group members for the WHO European Region.
Manuel de formation pour les agents de santé communautaire pour l'évaluation des signes de danger et l'administration d'un traitement préalable au transfert immédiat vers une structure de santé.
Ce manuel a été développé par le Programme Spécial de Recherche et de Formation concernant l...es Maladies Tropicales (TDR) pour aider à la formation des Agents de Santé Communautaire (ASC) sur l'utilisation de l'artésunate par voie rectale comme traitement de pré-transfert.
Ceci est fondé sur la stratégie de prise en charge intégrée des maladies de l'enfant (lMCI), et une publication antérieure "Caring for the sick child in the community» qui avait été produite par le Département Santé de la mère, du nouveau-né, de l'enfant et de l'adolescent de l'OMS.
more
Indem sie die Deklaration „Universal health coverage: moving together to build a healthier world“ unterzeichnet hat, hat die Bundesregierung dieses Ziel im September 2019 noch einmal bekräftigt. Sie hat außerdem zugesichert, sich verstärkt um bisher besonders Benachteiligte zu kümmern und d...arauf zu achten, niemanden zurückzulassen („leave no one behind“). Für alle in Deutschland lebenden Menschen müssen demnach die notwendigen Gesundheitsdienste diskriminierungsfrei zugänglich sein.
more
Rapports périodiques initiaux à cinquièmes des États parties
République centrafricaine
O objetivo deste documento é definir o papel dos serviços de APS/ESF no manejo e controle da infecção COVID-19, bem como disponibilizar os instrumentos de orientação clínica para os profissionais que atuam na porta de entrada do SUS a partir da transmissão comunitária de COVID-19 no Brasil.
Available in English, French and Spanish
Während hunderttausende Ukrainer ihr Land verlassen, kann sich die EU - wie schon 2015 - nicht auf die Verteilung der Kriegsvertriebenen einigen. Dennoch ist es dieses Mal anders: Der von allen EU-Staaten gebilligte, vorübergehende Schutz für Geflüchtete aus der Ukraine ermöglicht eine rasche, ...unbürokratische Aufnahme. Die Sprache in Medien und Politik ist eine andere. Was steckt dahinter? Eine Analyse mit zwei Expert*innen für Flucht und Ankunft.
more
Pathogens . 2021 Nov 16;10(11):1493.doi: 10.3390/pathogens10111493
.Chronic manifestations of Chagas disease present as disabling and life-threatening condi-tions affecting mainly the cardiovascular and gastrointestinal systems. Although meaningful research has outlined the different molecular mech...anisms underlying Trypanosoma cruzi’s infection and the host-parasite interactions that follow, prompt diagnosis and treatment remain a challenge, particu-larly in developing countries and also in those where the disease is considered non-endemic. This review intends to present an up-to-date review of the parasite’s life cycle, genetic diversity, virulence factors, and infective mechanisms, as well as the epidemiology, clinical presentation, diagnosis, and treatment options of the main chronic complications of Chagas disease.
more
The longlist of knowledge gaps is based on existing research agendas published in 2015 or later and expert input from reviewers of the first draft of the longlist. It only includes knowledge gaps focussing on a better
understanding of the relationship between global environmental change and human h...ealth, and finding an answer to the question of how best to protect human health against these new threats.
more
Chronic manifestations of Chagas disease present as disabling and life-threatening conditions affecting mainly the cardiovascular and gastrointestinal systems. Although meaningful research has outlined the different molecular mechanisms underlying Trypanosoma cruzi’s infection and the host-parasit...e interactions that follow, prompt diagnosis and treatment remain a challenge, particularly in developing countries and also in those where the disease is considered non-endemic. This review intends to present an up-to-date review of the parasite’s life cycle, genetic diversity, virulence
factors, and infective mechanisms, as well as the epidemiology, clinical presentation, diagnosis, and treatment options of the main chronic complications of Chagas disease.
more
This study was aimed to ascertain the clinical profile and management of patients with ischemic heart disease (IHD) and/or peripheral artery disease (PAD). In this observational and cross-sectional study developed in 80 hospitals throughout Spain, consecutive adults with stable IHD and/or PAD were i...ncluded. A total of 1089 patients were analyzed, of whom 65.3% had only IHD, 17.8% PAD and 16.9% both. A total of 80.6% were taking only one antiplatelet agent, and 18.2% were on dual antiplatelet therapy (mainly aspirin/clopidogrel). Almost all patients were taking ≥1 lipid lowering drug, mainly moderate-to-high intensity statins. IHD patients took ezetimibe more commonly than PAD (43.9% vs. 12.9%; p < 0.001). There were more patients with IHD that achieved blood pressure targets compared to PAD (<140/90 mmHg: 67.9% vs. 43.0%; p < 0.001; <130/80 mmHg: 34.1% vs. 15.7%; p < 0.001), LDL-cholesterol (<70 mg/dL: 53.1% vs. 41.5%; p = 0.033; <55 mg/dL: 26.5% vs. 16.0%; p = 0.025), and diabetes (HbA1c < 7%, with SGLT2i/GLP1-RA: 21.7% vs. 8.8%; p = 0.032). Modifications of antihypertensive agents and lipid-lowering therapy were performed in 69.0% and 82.3% of patients, respectively, without significant differences between groups. The use of SGLT2i/GLP1-RA was low. In conclusion, cardiovascular risk factors control remains poor among patients with IHD, PAD, or both. A higher use of combined therapy is warranted.
more